Breaking Finance News

RBC Capital Markets disclosed Clovis Oncology Inc (NDAQ:CLVS), hiking its price target to $81.00 earlier today

Having a price of $69.00, Clovis Oncology Inc (NDAQ:CLVS) traded -0.36% lower on the day. With the last stock price up 1.54% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. CLVS has recorded a 50-day average of $74.87 and a two hundred day average of $68.72. Trade Volume was down over the average, with 352,747 shares of CLVS changing hands under the typical 1,946,550

Stating a potential upside of 0.17%, RBC Capital Markets raised the target price of Clovis Oncology Inc (NDAQ:CLVS) to $81.00

On 8/17/2017, Evercore ISI released a statement about Clovis Oncology Inc (NDAQ:CLVS) upped the target price from $0.00 to $73.00 that suggested an upside of 0.06%.

Performance Chart

Clovis Oncology Inc (NDAQ:CLVS)

With a total market value of $0, Clovis Oncology Inc has with a one year low of $25.50 and a one year high of $99.45 .

A total of 8 equity analysts have released a ratings update on CLVS. 2 brokers rating the stock a strong buy, 0 firms rating the stock a buy, 6 firms rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $17.50.

Brief Synopsis About Clovis Oncology Inc (NDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *